Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Anders Mellemgaard
Consultant or Advisory Role - Boehringer Ingelheim
Sergey V. Orlov
No relevant relationships to disclose
Maciej Jerzy Krzakowski
No relevant relationships to disclose
Joachim Von Pawel
Consultant or Advisory Role - Daiichi Sankyo; Pfizer; Vertex
Maya Gottfried
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Mei-Lin Liao
No relevant relationships to disclose
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Julia Hocke
Employment or Leadership Position - Boehringer Ingelheim
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Silvia Novello
No relevant relationships to disclose
Jean-Yves Douillard
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Merck Serono; Roche
Honoraria - Amgen; AstraZeneca